<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920711</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696D2301</org_study_id>
    <secondary_id>2013-001747-31</secondary_id>
    <nct_id>NCT01920711</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction</brief_title>
  <acronym>PARAGON-HF</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the&#xD;
      reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF&#xD;
      with preserved ejection fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, randomized, double-blind, parallel group, active-controlled, study to&#xD;
      evaluate the efficacy and safety of sacubitril/valsartan compared to valsartan, on morbidity&#xD;
      and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.&#xD;
      Specifically, the study evaluated the effect of sacubitril/valsartan compared to the active&#xD;
      comparator valsartan in the reduction of the rate of CV death and total HF hospitalizations&#xD;
      in patients with HFpEF. The trial consisted of two periods: (1) a single-blind treatment&#xD;
      run-in epoch that lasted from 3 to 8 weeks, in which patients received valsartan 80 mg bid,&#xD;
      followed by sacubitril/valsartan 100 mg bid and (2) a double-blind randomized treatment epoch&#xD;
      (sacubitril/valsartan 200 mg bid or valsartan 160 mg bid). In this study, investigators were&#xD;
      responsible for assessing and submitting all events which could potentially fulfill the&#xD;
      criteria for the primary, secondary, or other clinical endpoints to a Clinical Endpoint&#xD;
      Committee (CEC). Investigator reported events were assessed by the CEC for adjudication.&#xD;
&#xD;
      For angioedema or angioedema-like events, investigators completed an Adjudication&#xD;
      Questionnaire for an Angioedema-like Event form. All angioedema reports were forwarded to an&#xD;
      Angioedema Adjudication Committee (AAC) by Novartis for assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2014</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.</measure>
    <time_frame>Total follow up time (up to 57 months)</time_frame>
    <description>The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association [NYHA] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction [LVEF] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline, 8 months</time_frame>
    <description>The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>Baseline, 8 months</time_frame>
    <description>Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With First Occurrence of a Composite Renal Endpoint</measure>
    <time_frame>Randomization to total follow-up time (up to 57 months)</time_frame>
    <description>Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>Randomization to total follow up time (up to 57 months)</time_frame>
    <description>Analysis for all-cause mortality using Cox's proportional hazards model.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4822</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.</description>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥45% by echo during screening epoch or&#xD;
             within 6 months prior to study entry.&#xD;
&#xD;
          -  Symptom(s) of heart failure (HF) and requiring treatment with diuretic(s) for HF at&#xD;
             least 30 days prior to study entry.&#xD;
&#xD;
          -  Current symptom(s) of HF (NYHA class II-IV)&#xD;
&#xD;
          -  Structural heart disease (left atrial enlargement or left ventricular hypertrophy)&#xD;
             documented by echocardiogram.&#xD;
&#xD;
          -  Elevated NT-proBNP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior measurement of LVEF &lt; 40%.&#xD;
&#xD;
          -  Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within&#xD;
             3 months , or urgent percutaneous coronary intervention within 3 months or and&#xD;
             elective PCI within 30 days prior to entry.&#xD;
&#xD;
          -  Any clinical event within the 6 months prior to entry could have reduced the LVEF&#xD;
             (e.g., MI, CABG), unless an echo measurement performed after the event confirms a LVEF&#xD;
             ≥45%.&#xD;
&#xD;
          -  Current acute decompensated HF requiring therapy.&#xD;
&#xD;
          -  Patients who require treatment with 2 or more of the following: an angiotensin&#xD;
             converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin&#xD;
             inhibitor.&#xD;
&#xD;
          -  Alternative reason for shortness of breath such as: significant pulmonary disease or&#xD;
             severe COPD, hemoglobin (Hgb) &lt;10 g/dl, or body mass index (BMI) &gt; 40 kg/m2.&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP &gt;150 mmHg and &lt;180 mmHg at&#xD;
             entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP &lt; 110&#xD;
             mmHg at entry.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310-1495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Covington</city>
        <state>Georgia</state>
        <zip>30014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hazel Crest</city>
        <state>Illinois</state>
        <zip>60429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lombard</city>
        <state>Illinois</state>
        <zip>60148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belzoni</city>
        <state>Mississippi</state>
        <zip>39038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901 3158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northport</city>
        <state>New York</state>
        <zip>11768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratoga Springs</city>
        <state>New York</state>
        <zip>12866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Livingston</city>
        <state>Texas</state>
        <zip>77351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-1615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1407</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Capital Federal</state>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Posadas</city>
        <state>Misiones</state>
        <zip>N3300AHX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad de Salta</city>
        <state>Provincia De Salta</state>
        <zip>A4406BPF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <state>San Miguel De Tucuman</state>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>3080</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000QID</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000IFL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AGP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DCO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000EVQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BSN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KET</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5022CPU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Formosa</city>
        <zip>P3600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis</city>
        <zip>D5702JRS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bundoora</city>
        <state>Victoria</state>
        <zip>3083</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunau</city>
        <zip>A5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Großgmain</city>
        <zip>5084</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>De Pinte</city>
        <zip>9840</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uberlandia</city>
        <state>Minas Gerais</state>
        <zip>38411 186</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80730 150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campina Grande do Sul</city>
        <state>PR</state>
        <zip>83430-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liberdade</city>
        <state>Sao Paulo</state>
        <zip>01504-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blumenau</city>
        <state>SC</state>
        <zip>89020 430</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13020-431</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14055-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Silistra</city>
        <zip>7500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolian</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thetford Mines</city>
        <state>Quebec</state>
        <zip>G6G 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <zip>132000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jinan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida Blanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varazdin</city>
        <state>HRV</state>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zadar</city>
        <zip>23000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <state>Czech Republic</state>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivancice</city>
        <state>Czech Republic</state>
        <zip>66491</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kladno</city>
        <state>Czech Republic</state>
        <zip>272 80</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liberec</city>
        <state>Czech Republic</state>
        <zip>460 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louny</city>
        <state>Czech Republic</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <state>Czech Republic</state>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <state>Czech Republic</state>
        <zip>30100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <state>Czech Republic</state>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roznov pod Radhostem</city>
        <state>Czech Republic</state>
        <zip>756 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svitavy</city>
        <state>Czech Republic</state>
        <zip>568 25</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trebic</city>
        <state>Czech Republic</state>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Usti nad Labem</city>
        <state>Czech Republic</state>
        <zip>400 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Znojmo</city>
        <state>Czech Republic</state>
        <zip>66902</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Policska</city>
        <state>CZE</state>
        <zip>57201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>CZE</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Usti nad Labem</city>
        <state>CZE</state>
        <zip>400 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>CZE</city>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolin</city>
        <zip>280 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marianske lazne</city>
        <zip>353 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayonne</city>
        <state>Bayonne Cedex</state>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beziers Cedex</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>F-69001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pontoise</city>
        <zip>F-95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Homburg</city>
        <zip>61348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13405</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dessau-Roßlau</city>
        <zip>06846</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eilenburg</city>
        <zip>D 04838</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elsterwerda</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22041</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22765</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hassloch</city>
        <zip>67454</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidenau</city>
        <zip>01809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heppenheim</city>
        <zip>64646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ingelheim</city>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kleve</city>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loehne</city>
        <zip>32584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lutherstadt Wittenberg</city>
        <zip>06886</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lüneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meißen</city>
        <zip>01662</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muehldorf Am Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muehldorf</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munich</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northeim</city>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oschatz</city>
        <zip>04758</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Papenburg</city>
        <zip>26871</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89077</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wermsdorf</city>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weyhe</city>
        <zip>28844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <state>GR</state>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larissa</city>
        <state>GR</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>10110</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1042</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H 1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mako</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H 6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>H-8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guntur</city>
        <state>Andhra Pradesh</state>
        <zip>522001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>532 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Haryana</state>
        <zip>160 030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>683 594</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil NADU</state>
        <zip>600037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600081</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil NADU</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lower Galilee</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Giborim, Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aosta</city>
        <state>AO</state>
        <zip>11100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cortona</city>
        <state>AR</state>
        <zip>52044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozzilli</city>
        <state>IS</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vimercate</city>
        <state>MI</state>
        <zip>200059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ariccia</city>
        <state>RM</state>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palmanova</city>
        <state>UD</state>
        <zip>33057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Daniele Del Friuli</city>
        <state>UD</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saronno</city>
        <state>Va</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Venezia</city>
        <state>VE</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seto-city</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogaki-city</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi city</city>
        <state>Gunma</state>
        <zip>371 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki city</city>
        <state>Hyogo</state>
        <zip>660 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920 8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020 0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanonji-city</city>
        <state>Kagawa</state>
        <zip>769-1695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takamatsu city</city>
        <state>Kagawa</state>
        <zip>760 8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236 0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai city</city>
        <state>Miyagi</state>
        <zip>980 8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashihara city</city>
        <state>Nara</state>
        <zip>634 8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kusatsu city</city>
        <state>Shiga</state>
        <zip>525 8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyeonggi do</city>
        <state>Bucheon Si</state>
        <zip>422-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk Do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26427</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bundang Gu</city>
        <state>Gyeonggi Do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <state>KOR</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>KOR</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705 718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torreon</city>
        <state>Coahulia</state>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan del Rio</city>
        <state>Queretaro</state>
        <zip>76800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potosí</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Apeldoorn</city>
        <state>DZ</state>
        <zip>7334</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <state>NL</state>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almelo</city>
        <state>PP</state>
        <zip>7609</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blaricum</city>
        <zip>1261 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hardenberg</city>
        <zip>7770 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loerenskog</city>
        <zip>NO 1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tromsoe</city>
        <zip>NO-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellavista</city>
        <state>Lima</state>
        <zip>CALLAO 02</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jesus Maria</city>
        <state>Lima</state>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miraflores</city>
        <state>Lima</state>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Manila</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90 549</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-157</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-548</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05 825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-645</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31 501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sandomierz</city>
        <zip>27 600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa/Anin</city>
        <zip>04-761</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-154</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41 800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pitesti</city>
        <state>Arges</state>
        <zip>110438</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <state>District 1</state>
        <zip>014461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <state>Jud. Dolj</state>
        <zip>200497</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sibiu</city>
        <state>Jud. Iasi</state>
        <zip>550371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300362</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arad</city>
        <zip>310158</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baia Mare</city>
        <zip>430222</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540143</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300041</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirov</city>
        <zip>610035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194295</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.- Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beograd</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>768828</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brezno</city>
        <state>Slovak Republic</state>
        <zip>977 42</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarno</city>
        <state>Slovak Republic</state>
        <zip>94501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <state>Slovak Republic</state>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namestovo</city>
        <state>Slovak Republic</state>
        <zip>02901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <state>Slovak Republic</state>
        <zip>01701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <state>Slovak Republic</state>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>821 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>841 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>842 31</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <zip>98439</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 88</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94002</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trebisov</city>
        <zip>075 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <state>Kwa-Zulu Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alberton</city>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tongaat</city>
        <zip>3300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Western Cape</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almeria</city>
        <state>Andalucia</state>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marbella</city>
        <state>Andalucia</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sanlúcar de Barrameda</city>
        <state>Andalucia</state>
        <zip>11540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Joan Despi</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villamartin</city>
        <state>Cadiz</state>
        <zip>11650</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aranda de Duero</city>
        <state>Castilla Y Leon</state>
        <zip>09400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leon</city>
        <state>Castilla Y Leon</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lerida</city>
        <state>Cataluna</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alzira</city>
        <state>Comunidad Valenciana</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merida</city>
        <state>Extremadura</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olot</city>
        <state>Girona</state>
        <zip>17800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Danderyd</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlstad</city>
        <zip>652 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>222 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vasteras</city>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Biel</city>
        <zip>2502</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Taipei</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>71004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yilan</city>
        <zip>26058</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haydarpasa Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34304</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pendik / Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sivas</city>
        <zip>58140</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Wycombe</city>
        <state>Buckinghamshire</state>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton on Tees</city>
        <state>Cleveland</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darlington</city>
        <state>Co Durham</state>
        <zip>DL3 8SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>County Durham</state>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dorchester</city>
        <state>Dorset</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <state>GBR</state>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldham</city>
        <state>Lancashire</state>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portadown</city>
        <state>Nothern Ireland</state>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wansford</city>
        <state>Peterborough</state>
        <zip>PE8 6PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gateshead</city>
        <state>Tyne And Wear</state>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clydebank</city>
        <state>West Dumbartonshire</state>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheshire</city>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport</city>
        <zip>NP20 2UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiltshire</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wrexham</city>
        <zip>LL13 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <results_first_submitted>May 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2020</results_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>preserved ejection fraction</keyword>
  <keyword>diastolic heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT01920711/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT01920711/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4822 patients were randomized at 755 sites in 43 countries. 2419 participants were randomized into the LCZ696 treatment group and 2403 were randomized into the valsartan treatment group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Valsartan</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2419"/>
                <participants group_id="P2" count="2403"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2055"/>
                <participants group_id="P2" count="2030"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="373"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set totaled 4822 patients. Full Analysis Set consisted of 4796 patients: primary efficacy population used in the analyses for all efficacy endpoints, includes all randomized patients minus 26 patients excluded due to GCP violations. Safety set included all randomized patients minus 1 patient who did not receive study drug: 4821 patients</population>
      <group_list>
        <group group_id="B1">
          <title>LCZ696</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Valsartan</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2419"/>
            <count group_id="B2" value="2403"/>
            <count group_id="B3" value="4822"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="415"/>
                    <measurement group_id="B2" value="415"/>
                    <measurement group_id="B3" value="830"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2004"/>
                    <measurement group_id="B2" value="1988"/>
                    <measurement group_id="B3" value="3992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1247"/>
                    <measurement group_id="B2" value="1244"/>
                    <measurement group_id="B3" value="2491"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1172"/>
                    <measurement group_id="B2" value="1159"/>
                    <measurement group_id="B3" value="2331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1975"/>
                    <measurement group_id="B2" value="1958"/>
                    <measurement group_id="B3" value="3933"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.</title>
        <description>The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association [NYHA] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction [LVEF] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.</description>
        <time_frame>Total follow up time (up to 57 months)</time_frame>
        <population>Full Analysis Set - This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.</title>
          <description>The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association [NYHA] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction [LVEF] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.</description>
          <population>Full Analysis Set - This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2407"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Composite Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894"/>
                    <measurement group_id="O2" value="1009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hospitalizations for heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690"/>
                    <measurement group_id="O2" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Composite Events</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0587</p_value>
            <p_value_desc>1-sided p-value 0.0294</p_value_desc>
            <method>Proportional Rates Model (LWYY)</method>
            <method_desc>Treatment as fixed-effect factor and stratified by region and with robust variance estimate.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.8698</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7526</ci_lower_limit>
            <ci_upper_limit>1.0052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Hospitalizations for heart failure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0556</p_value>
            <p_value_desc>1-sided p-value 0.0278</p_value_desc>
            <method>Joint Frality Model</method>
            <method_desc>Treatment and region as fixed-effect factors</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.8511</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7216</ci_lower_limit>
            <ci_upper_limit>1.0039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cardiovascular Death</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6241</p_value>
            <p_value_desc>1-sided p-value 0.3120</p_value_desc>
            <method>Cox's proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9531</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7863</ci_lower_limit>
            <ci_upper_limit>1.1551</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.</description>
        <time_frame>Baseline, 8 months</time_frame>
        <population>Full Analysis Set-This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.</description>
          <population>Full Analysis Set-This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
          <units>Points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2407"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5073" spread="0.3709"/>
                    <measurement group_id="O2" value="-2.5338" spread="0.3729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Clinical Summary Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0510</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean of Difference</param_type>
            <param_value>1.0264</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0047</ci_lower_limit>
            <ci_upper_limit>2.0576</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class</title>
        <description>Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.</description>
        <time_frame>Baseline, 8 months</time_frame>
        <population>Full Analysis Set - This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints. However, this endpoint only includes those participants who had assessments completed for both Baseline and Month 8 visits; as that is the only way a change could be calculated and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class</title>
          <description>Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.</description>
          <population>Full Analysis Set - This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints. However, this endpoint only includes those participants who had assessments completed for both Baseline and Month 8 visits; as that is the only way a change could be calculated and analyzed.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2407"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved (n=2316, 2302)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2316"/>
                    <count group_id="O2" value="2302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged (n=2316, 2302)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2316"/>
                    <count group_id="O2" value="2302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1767"/>
                    <measurement group_id="O2" value="1792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened (n=2316, 2302)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2316"/>
                    <count group_id="O2" value="2302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NYHA Class Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Repeated measures cumulative odds model</method>
            <method_desc>The response variable is the change from baseline to any scheduled time points up to Month 8.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4475</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1294</ci_lower_limit>
            <ci_upper_limit>1.8552</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With First Occurrence of a Composite Renal Endpoint</title>
        <description>Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.</description>
        <time_frame>Randomization to total follow-up time (up to 57 months)</time_frame>
        <population>Full Analysis Set -This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With First Occurrence of a Composite Renal Endpoint</title>
          <description>Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.</description>
          <population>Full Analysis Set -This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2407"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite renal endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching ESRD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50% decline in eGFR from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Composite renal endpoint</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Cox's proportional hazards model</method>
            <method_desc>Treatment as fixed factor and stratified by region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3312</ci_lower_limit>
            <ci_upper_limit>0.7673</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Renal Death</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9588</p_value>
            <method>Cox's proportional hazards model</method>
            <method_desc>Treatment as fixed factor and stratified by region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9295</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0581</ci_lower_limit>
            <ci_upper_limit>14.861</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reaching ESRD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2484</p_value>
            <method>Cox's proportional hazards model</method>
            <method_desc>Treatment as fixed factor and stratified by region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5774</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2272</ci_lower_limit>
            <ci_upper_limit>1.4672</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&gt;=50% decline in eGFR from baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Cox's proportional hazards model</method>
            <method_desc>Treatment as fixed factor and stratified by region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.4407</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2798</ci_lower_limit>
            <ci_upper_limit>0.6942</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>Analysis for all-cause mortality using Cox's proportional hazards model.</description>
        <time_frame>Randomization to total follow up time (up to 57 months)</time_frame>
        <population>Full Analysis Set -This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>Analysis for all-cause mortality using Cox's proportional hazards model.</description>
          <population>Full Analysis Set -This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2407"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All-cause mortality</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6846</p_value>
            <method>Cox's proportional hazards model</method>
            <method_desc>Treatment as fixed factor and stratified by region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9696</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8352</ci_lower_limit>
            <ci_upper_limit>1.1255</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 5 years.</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. Safety set included all randomized patients minus 1 patient who did not receive study drug: 4821 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>LCZ696</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Valsartan</title>
          <description>Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid</description>
        </group>
        <group group_id="E3">
          <title>All Patients</title>
          <description>Total patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="347" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="357" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="704" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1424" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1416" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2840" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired haemophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Splenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="307" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="340" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="380" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="720" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mitral valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventricular dyssynchrony</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Congenital coronary artery malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Congenital megaureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>LUMBAR syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vertebral artery hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vestibular ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypercorticoidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Parathyroid hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Narrow anterior chamber angle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Appendiceal mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic gastroenteropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal wall thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal strangulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Concomitant disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Impaired self-care</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Implant site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Medical device discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Treatment noncompliance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholelithiasis migration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cryptogenic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gallbladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemobilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nonalcoholic fatty liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Primary biliary cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bacterial rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Complicated appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Embolic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Genital herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Human anaplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intracranial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Meningitis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="340" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Septic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Severe acute respiratory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arterial bypass occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coronary bypass stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Extra dose administered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypobarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nerve root injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Radiation proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sedation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Stomal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bleeding time abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood osmolarity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Influenza virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Precancerous cells present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ventilation/perfusion scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Visual field tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiometabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>CREST syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chest wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myositis ossificans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gallbladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hormone-refractory prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malignant mediastinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myeloproliferative neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oral haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sarcoma uterus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin neoplasm bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tumour compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tumour embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vaginal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Waldenstrom's macroglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebellar haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidotic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mixed dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Multiple system atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post stroke epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pseudoradicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Resting tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spinal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>VIth nerve paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vascular parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device defective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with mixed anxiety and depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Behaviour disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Delirium febrile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Organic brain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="200" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glomerulonephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal vein stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Endometrial thickening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Scrotal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Mediastinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Presbyphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Butterfly rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diabetic wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ischaemic skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Rhinophyma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vasculitic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Living in residential institution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haemorrhagic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2005" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="1995" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="4000" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="380" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="487" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="494" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="154" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="186" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="357" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="205" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="190" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="349" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="374" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="384" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="197" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="284" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="511" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="178" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="298" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="536" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="305" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="319" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="421" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="240" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="331" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="618" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="334" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="453" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="539" subjects_at_risk="4821"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="529" subjects_at_risk="2419"/>
                <counts group_id="E2" subjects_affected="379" subjects_at_risk="2402"/>
                <counts group_id="E3" subjects_affected="908" subjects_at_risk="4821"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

